Results
Release of pro-inflammatory cytokines in response of microglia to activation
Microglial function was assessed by quantifying TNF -α and IL -6 secretion after stimulation (see Methods) .
The baseline of secreted cytokines in untreated cells was below detection levels . TNFa and IL-6, were only
detected 8 and 24 h after activation. At 8 h post activation, the absolute levels of TNF -α and IL -6 were
approximately 430 and 6 pg/ µg, respectively. We normalized the amount of protein released to the basal
level measured for bzATP, 24 h after exposure (Figure 1A) The level of induction was >20 fold higher than
that in the presence of bzATP. While the absolute level of IL6 was lower than that of TNF -α, the induction
was approximately 50-100-fold for the combination of bzATP/LPS (Figure 1B). The pro-inflammatory cytokine
secretion increased significantly and consistently for 48 h. However, IL-6 secretion was slightly less stable and
was sensitive to cell density (at a range of 1 x 105 to 5 x 105 cells per well). We analyzed the transcript levels
of Tnf and Il6 in untreated and the stimulated cells. Tnf was detectable at low levels in naïve cells but not Il6
in accordance with the results from secreted cytokines. While monitoring mRNA levels is valid in a few hours
post activation, measurement of the secreted proteins, require s a longer time for completing ribosomal
translation, folding, post modifications and trafficking. Similar to the results from Figure 1B, the secretion of
IL-6 continues to rise, which is consistent with the increase in Il6 transcript levels. These findings indicate that
the pro-inflammatory response is robust and coordinated, while the activation kinetics is unique for the
different cytokines.
Figure 1. Quantitation of TNFa and IL-6 released from primary neonatal murine microglial culture following
stimulation. (A) Relative induction of TNFa protein 24 h post stimulation. Values are normalized to the levels
of TNF a in the presence of bzATP. (B) Relative induction of IL -6 protein 24 h post stimulation. Values are
normalized to the levels of IL-6 in the presence of bzATP. Notably, the basal level of TNFa and IL-6 were below
detection in unstimulated cells. Samples were collected from conditioned media supplemented with BSA,
harvested, and measured 24 h after stimulation. A mean and standard deviation (s.d.) of 3 experiments in
triplicates.
The alternation in miRNA profile in the presence of bzATP is minimal
We sought to follow the temporal behavior of the activated cells by the change in the miRNA profiles. None
of the 372 identified miRNAs was significantly changed 3 h after exposure to BzATP (restricted to the
predetermined expression threshold, see Methods ), and o nly a minimal change in miRNA profile was
detected 8 h after exposure. Among all 372 miRNAs only three were statistically significant (i.e., DEMs), miR-
146b-3p and miR-146b-5p were upregulated to a level of 1.66 and 1.41 relative to untreated cells (N.T.) while
miR-3963 was downregulated. Notably, t he degree of downregulation of miR-3963 was 5.8 -fold in the
presence of bzATP/LPS after 8 h, but did not reach the maximal level shown by bzATP alone (10.9-fold). From
these results we conclude that the addition of bz ATP alone was unable to activate the full response of
microglial cells, but potentially primes miR-146b, and suppresses miR-3963.
Temporal expression miRNA profiles following bzATP/LPS activation
.CC-BY-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 14, 2025. ; https://doi.org/10.1101/2025.04.11.648484doi: bioRxiv preprint
5
As we observed a minimal response of pro -inflammatory cytokine secretion by exposure cells to bzATP
(Figure 1), we analyzed the miRNA-seq results in cells that were subjected to the activation protocol by bzATP
and LPS (bzATP/LPS). We tested the cells’ miRNA transcriptome at 3 h and 8 h after exposure. The
experimental groups were separated using unsupervised clustering based on the miRNA expression data
(Supplementary Figure S1). We identified 372 miRNAs that represent 345 uniquely labeled using miRNA-seq
analysis. We measured the fold change relative to untreated cells and set a relaxed threshold on the fold
change (log2FC >|0.33|). Each identified miRNA was assigned by its expression trend relative to that in the
untreated cells as well as to the expression level monitored at a previous time point.
Figure 2A shows the partitions of miRNAs into modules according to their expression pattern s. We divided
all miRNAs into nine expression patterns by their paired expression at the time points (expression trends are
defined as in Supplementary Table S1). Each cluster is indicated by the number of miRNAs that match the
expression pattern. As expected, most miRNAs (59%) were marked as unchanged even after 8 h (labeled
‘same–same’). Another 14% were characterized by a delayed response (i.e., labeled as ‘same-up’ and ‘same-
down’; Figure 2A, black color). We found that 18% of the miRNAs were already upregulated in the short time
frame (3 h post acti vation) with more of them displaying a transient expression wave ( Figure 2A, orange
color). Only 6 miRNAs exhibited a consistant and robust increase in expression ( Figure 2B). These miRNAs
are expected to carry the signature for maintaining the activated state of the microglia culture. The identified
miRNAs include miR-146b, miR-155-5p, miR-29b-2, miR-5121 and miR-6240. For 11% of the miRNAs,
expression was suppressed compared to that in naïve cells (Figure 2A, blue color) and the expression of miR-
301a and miR-760 was monotonically downregulated ( Figure 2C ). We conclude that many miRNAs are
subjected to temporal regulation during the initial hours following the activation protocol by bzATP/LPS.
Expression modules for all miRNAs are listed in Supplementary Table S2.
Figure 2. Trends in gene expression of microglial miRNAs following activation protocol with BzATP/LPS for 3
h and 8 h. (A) The 345 identified miRNAs are classified into nine modules based on their combined expression
trend (up, down or same, and their combinations). For definition and thresholds see details in Supplementary
Table S1). The baseline (log(FC) = 0) is shown by horizontal red line. The miRNAs associated with fast kinetics
are colored for up (orange), same (black) and down (blue). The number of miRNAs that belong to each module
is indicated. (B) The fold change of the miRNAs that are labelled ‘up -up’. (C) The fold change of the miRNAs
that are labelled ‘down-down’. The analysis is based on the data in Supplementary Table S2.
.CC-BY-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 14, 2025. ; https://doi.org/10.1101/2025.04.11.648484doi: bioRxiv preprint
6
Activation of microglia by bzATP/LPS alters the miRNAs expression profile, including abundant miRNAs
Table 1 lists 20 miRNAs that are highly expressed (>100 CPM) and were significantly changed 8 h following
activation by bzATP/LPS. The list shows miRNA s by their mature variants (i.e., 5p or 3p) and rank s them by
the fold change relative to N.T. cells. Most of the miRNAs were upregulated, with maximal fold change seen
for miR-155-5p. The expression of the most abundant miRNA, miR-21a-5p (accounts for 16.2% of all identified
miRNAs), was strongly upregulated ( Table 1, 1.59-fold). It is anticipated that even a moder ate increase in
expression of an abundant miRNA (albeit by ~ 60%) may indirectly affect the stability of other miRNAs, thus
impacting global cell regulation [31]. Not all abundant miRNA families were altered following activation .
Although there are 20 such miRNAs that belong to the let-7 family, which accounts for >30% of all miRNAs in
the cells, they remain unchanged (an exception is the downregulation of let-7b-5p, Table 1). We concluded
that the i n vitro activation of the primary neonatal microglial culture is specific, resulting in substantial
changes in miRNA profiles involving 15% of the abundant miRNAs (≥100 CPM). Among these differentially
expressed miRNAs (DEMs) also the highly abundant miRNAs such as miR-21a, miR-146b and miR-7a.
Table 1. List of abundant (average CPM ≥100) DEMs 8 h post activation in the presence of bzATP/LPS
miRNA FDR Fold change Ave. CPM Trend
mmu-miR-155-5p 2.04E-15 5.14 231.0 Up
mmu-miR-146b-5p 3.29E-16 2.15 35,262.0 Up
mmu-miR-146a-5p 3.17E-07 1.64 11,147.5 Up
mmu-miR-21a-5p 3.06E-13 1.59 161,946.4 Up
mmu-miR-5099 8.14E-07 1.55 4,425.2 Up
mmu-miR-7a-5p 7.51E-09 1.50 16,738.0 Up
mmu-miR-125a-3p 2.87E-06 1.44 106.7 Up
mmu-miR-99b-3p 3.54E-06 1.40 523.7 Up
mmu-miR-22-5p 1.27E-04 1.40 169.7 Up
mmu-miR-22-3p 9.06E-08 1.39 3,072.8 Up
mmu-miR-222-5p 1.90E-05 1.37 243.8 Up
mmu-miR-671-3p 5.08E-03 1.33 238.8 Up
mmu-miR-361-3p 6.20E-05 1.33 330.7 Up
mmu-miR-26a-5p 2.87E-06 0.79 15,464.0 Down
mmu-miR-101a-3p 2.07E-05 0.79 825.0 Down
mmu-miR-504-5p 9.77E-03 0.78 114.8 Down
mmu-miR-9-5p 2.87E-06 0.77 2,290.4 Down
mmu-miR-378a-3p 1.47E-07 0.76 4,776.9 Down
mmu-let-7b-5p 1.95E-03 0.76 4,927.1 Down
mmu-miR-3968 7.01E-03 0.73 142.6 Down
Applying the same analysis for the miRNAs at an earlier phase of activation (3 h) showed that only 10
upregulated miRNAs were identified and none were downregulated. Among these DEMs we identified miR-
21a and miR-146b, as well as abundant miRNAs that are only significant at the early phase of the activation
(e.g., miR-125a, miR-125b; Supplementary Table S3). We conclude that the establishment of fully activated
microglia is reflected by the temporal specificity in miRNA profiles.
Dynamics of differentially expressed miRNAs (DEMs) by bzATP/LPS activation
Activation of the primary microglial culture by bzATP/LPS changed the expression profile of miRNAs . Of the
372 mapped miRNAs that were expressed in substantial amounts, 38.8% are expressed with ≥100 CPM
(counts per million). Mapping led to minor duplication (with 345 uniquely labeled mature miRNA s defined
also by their 5p and 3p arms from the precursor pre -miRNAs. Figure 3A shows that the majority of miRNAs
have a low expressio n, with 50% of the miRNAs below 50 CPM and only 14 with >20,000 CPM. This set
.CC-BY-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 14, 2025. ; https://doi.org/10.1101/2025.04.11.648484doi: bioRxiv preprint
7
accounts for more than 73% of all cellular miRNAs (Supplementary Table S3. We report that as in other cells,
the miRNA expression level in microglial cells ranges over 5 orders of magnitude.
Figure 3. A global view of miRNAs statistics in microglia culture and time -dependent DEMs following
activation. (A) Partition of the 372 identified miRNAs by their number of miRNAs by their expression level bins
(orange, CPM) and total counts (blue). (B) A list of 33 significant DEMs 3 h post activation. (C) A list of 57
significant DEMs 8 h post-activation. The lists are sorted by fold change values. Vertical red dashed lines mark
the differential expression by 2 -fold, for underregulated and upregulated expression trend. The red frame
around the miRNA names marks the miRNAs that were differentially expressed by ≥1.5-fold.
In all cells, the post-transcriptional regulation mediated by miRNAs on translational arrest is expected to be
fast and transcriptionally independent [32]. We therefore tested the dynamics of miRNA at two time points
following stimulation by bzATP/LPS (Figure 3). Normalized expression levels of all identified miRNAs are listed
in Supplementary Table S4. There were 33 and 57 DEMs among the 372 miRNAs that met the statistically
significant threshold (FDR ≤0.05) for the short -term (3 hours, Figure 3B) and long-term (8 hours, Figure 3C)
activation protocols, respectively, while 50% of them had a fold change of ≥|1.5|.
A small set of temporally responsive miRNAs dictates the establishment of the fully activated microglia
Inspection of the results from the miRNA s that are consistently upregulated according to the set of time -
dependent unique DEMs allowed us to infer the contribution of miRNAs in establishing the act ivated
microglial state, but also highlighted examples of transient expression. Figure 4 shows the DEMs along the
activation timeline. Figure 4A present a Venn diagram with most DEMs identified for the 3 h and 8h activation
paradigms (Supplementary Figure S2). Only 9 miRNAs are unique to the early time point. Furthermore, more
than half of the DEMs at 8 h are also unique (27 DEMs), with similar numbers of u p-and downregulation.
Figure 4B (left) illustrates instances of DEMs where their fold change was maximal at the early time point.
For example, the miR-155-3p was upregulated by 22-fold at 3h and 7.6-fold at 8 h of activation. An opposite
trend where the fold change at a later time point continues to increase, is shown (Figure 4B, right). The miR-
132-5p and miR-155-3p show maximal expression at 3 h and remain substantially high also at 8 h, while that
of miR -155-5p and mir -146b are maximal 8 h post activatio n. These miRNAs exhibit strong temporal
sensitivity (≤30% difference between the two time points. We concluded that these miRNAs are of a special
.CC-BY-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 14, 2025. ; https://doi.org/10.1101/2025.04.11.648484doi: bioRxiv preprint
8
interest as their levels may dictate a time-dependent regulation of the microglial culture that was shifted to
new inflammatory states.
To further test the dynamics of miRNAs, we focused on miRNAs that were significantly altered between the
two time points during microglia activation (3 h and 8 h). Figure 4C displays an MA plot of time-dependent
fold change versus mean expression post activation (Supplementary Table S5). We identified 15 miRNAs (4%)
that are temporal DEMs (T-DEMs), with 5 that are maximally changed at the 3 h time point (marked red) and
10 that were further altered at a later time point (8 h, colored blue). The direct time-dependent comparison
highlighted several miRNAs that are more sensitive to the dynamics of the activation process. This includes
miR-455-5p, mir-365-2-5p, and miR-139-3p. An opposite trend (i.e., maximal expression occurs at 8 h post
activation) included the following T -DEMs: mir-146b-3p, miR-664-3p, miR-671-3p, miR-155-5p, miR-7a-5p,
miR-146a-5p and miR -365-3p. We observed that miR -365 showed a temporal dynamic , while different
variants of miR-365 exhibited an opposite temporal trend (miR-365-2-5p and miR-365-p).
Figure 4. Dynamics of DEMs following activation of microglial culture. (A) Venn diagram of the DEMs of two
time points (3 h and 8 h). The unique set that are not shared by both time points are listed. Included all
significant DEMs (FDR ≤0.05) and log10(FC) of >|0.33| relative to N.T. cells. The listed names of DEGs are
colored as up-and downregulated DEMs by red and green font, respectively. (B) Based on the overlap in A,
representative DEMs are listed with a change difference >30% between the 3 h and 8 h of cell activation
relative to N. T. The listed DEMs show ‘up-down’ (left) and ‘up-up’ (right). (C) MA plot of the log2(FC) relative
to the CPM (in log) for the 372 identified miRNAs. The temporal DEMs (T -DEMs) are colored by the change
expression trends with expression of 8 h > 3 h in blue and 3 h > 8 h in red. Gray are miRNAs t hat showed no
temporal expression pattern. The change in expression was determined by a threshold of log2(FC) > |0.33|
and an FDR q-value < 0.05.
Temporal expression of a set of miRNAs is coupled with differentially expressed inflammatory genes
The exposure of the cells to bzATP/LPS led to a group of miRNAs to change their expression (Figure 4C). We
tested whether these T-DEMs affected the establishment of the microglial inflammatory state. We mapped
miRNAs to their appropriate targets and limited our analysis to miRNA-mRNA pairs that were experimentally
validated. The list of T-DEMs (Supplementary Table S3) includes miRNAs that are classified as early and late
responders, based on the time point of their maximal expression (3 h or 8 h post-activation). We merged T-
DEMs with RNA-seq data that were collected from microglia under identical activation conditions [15] and
used miRNet 2.0 platform by its multiple -modality capability. The list of mRNA -seq results included 7 ,970
genes (FDR ≤0.05, filtered for coding genes) among which 149 were identified as direct targets in microglia
(Supplementary Table S6 ). The rest of the genes were either not expressed in microglia or fai led our
thresholds. We focused on the 25 genes with a substantial temporal expression change (T -DEGs with
.CC-BY-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 14, 2025. ; https://doi.org/10.1101/2025.04.11.648484doi: bioRxiv preprint
9
log2(FC)<|1|). All listed miRNA -target pairs shown were validated experimentally, and were identified of
microglia as T-DEGs (Table 2).
Table 2. T-DEMs and their experimental validated targets based on bzATP/LPS microglia RNA-seq data.
a miRNA signified by temporal pattern. The early (E) indicate maximal expression 3 h following activation. The
other miRNAs are signified as late pattern (i.e., max imal expression at 8 h post activation). The abundant
miRNAs with an average CPM >200 is marked in bold.
Table 2 lists 21 of these miRNA -targets (filtered by an expression threshold of ≥10 CPM) along with the ir
statistical properties. Several observations emerged regarding the potential impact of miRNAs on the direct
targets: (i) Most listed miRNAs are abundant (>200 CPM, bold). Extremely abundant miRNAs include miR-7a-
5p and miR-146a-5p with expressed levels of 16,738 and 11,147 CPM, respectively. (ii) miR-155 is associated
with many of the targets (11 of 21). (iii) Some of the target genes are ver y highly expressed in microglia.
Examples include Tnf (CPM 5250.7), Nlrp3 (CPM 1000) and Nfkb1 (CPM 533.3). (iv) Among the listed targets,
five were strongly upregulated compared to naïve cells (DEMs with log2(FC)<|1|) , with Nos2 and Tnf a
showing fold change of 29.13 and 18.92, respectively.
Figure 5A shows the results of miRNet 2.0, centered around a small set of T-DEMs. It is evident that miR-155-
5p is a major hub, with a large number of paired mRNA genes, and some genes are regulated by more than
one miRNA. Revisiting the results from miR-155-5p shows that it is strongly upregulated (22-fold) just 3 h of
post-activation and remains high at 8 h. The direct targets of miR -155 are Socs1 (suppressor of cytokin e
Validated
target Gene name miRNAa
(E: 3h >8h)
FDR
T-DEG
(3h-8h)
DEG
Ave.
CPM
FC
T-DEG
(3h>8h)
FC
DEG (8h
to N.T.)
Camk2d calcium/calmodulin-dependent protein
kinase II, delta miR-146a-5p 1.2E-18 47.2 0.50 1.31
Dnajb2 DnaJ heat shock protein family (Hsp40)
member B2 E: miR-155-3p 1.4E-15 16.0 2.17 1.90
Hbp1 high mobility group box transcription
factor 1 miR-155-5p 3.2E-14 16.3 2.05 0.68
Il6ra interleukin 6 receptor, alpha miR-155-5p 8.2E-17 18.3 2.58 0.54
Inpp5d inositol polyphosphate-5-phosphatase D miR-155-5p 5.2E-25 178.1 2.20 1.04
Jarid2 jumonji, AT rich interactive domain 2 miR-155-5p 6.5E-21 35.0 0.42 2.29
Mbp myelin basic protein miR-7a-5p 4.7E-21 71.5 2.10 0.54
Mfsd6 major facilitator superfamily domain
containing 6
miR-155-5p
miR-365-3p 4.9E-22 116.0 2.06 1.35
Mitf melanogenesis associated transcription
factor E: miR-155-3p 1.3E-28 354.5 0.34 1.05
Mllt3 myeloid/lymphoid or mixed-lineage
leukemia; translocated to, 3
miR-146a-5p
miR-146b-5p 2.9E-14 12.0 2.41 0.71
Nfkb1 nuclear factor of kappa light polypeptide
gene enhancer in B cells 1, p105 miR-146b-5p 3.6E-26 523.3 0.43 2.59
Nlrp3 NLR family, pyrin domain containing 3 miR-7a-5p 1.6E-29 1000.0 0.25 3.85
Nos2 nitric oxide synthase 2, inducible miR-146a-5p 6.0E-17 22.6 3.10 39.13
Pax6 paired box 6 miR-7a-5p 6.2E-14 12.6 2.53 0.50
Pik3r1 phosphoinositide-3-kinase regulatory
subunit 1 E: miR-132-5p 1.2E-20 47.4 2.16 0.81
Ptprj protein tyrosine phosphatase, receptor
type, J miR-155-5p 1.0E-22 392.8 0.42 1.89
Relb avian reticuloendotheliosis viral (v-rel)
oncogene related B miR-146a-5p 3.5E-26 56.2 0.34 1.10
S1pr1 sphingosine-1-phosphate receptor 1 miR-155-5p 2.1E-15 10.9 4.13 0.30
Tnf tumor necrosis factor E: miR-132-5p 4.8E-28 5250.7 0.29 18.92
Trp53inp1 transformation related protein 53
inducible nuclear protein 1 miR-155-5p 1.1E-16 18.3 3.24 0.57
Tspan14 tetraspanin 14 miR-155-5p 9.2E-20 41.9 2.32 0.94
.CC-BY-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 14, 2025. ; https://doi.org/10.1101/2025.04.11.648484doi: bioRxiv preprint
10
signaling 1) and Inpp5d (inositol polyphosphate-5-phosphatase D), leading to enhanced NF-kB signaling and
inflammation. In addition, Tnf acts as a hub in the inflammatory network (Figure 5B). It is paired with T-DEM
miR-132-5p which is maximally expressed 3 h after exposing the cells to bzATP/LPS (Table 2). The expression
at 8 h of the Tnf transcript is 3.4 -fold higher than at 3 h. The miR -132 is highly conserved between humans
and mice and has been shown as a regulator of neural signaling, where its dysregulation contributes to axonal
damage. A direct interaction of miR -132 with Tnf transcript remains questionable. Still, miR -132-5p
negatively regulates the release of TNF, possibly by targeting upstream regulators like NF-κB [33]. Although
speculative, it is likely that the presence of miR-132-5p at early time point, and its reduced amounts at later
stages, led to a delayed accumulation of Tnf transcripts in activated microglial culture s. We show that miR-
146a-5p is paired with the Nos2 (nitric oxide synthase 2, Table 2). Overexpression of miR-146a-5p in the BV2
microglial cell line reduced the expression of iNOS, encoded by Nos2 gene [34]. A similar effect
was observed in miR -146a knockout mice, which resulted in the overproduction of pro -inflammatory
cytokines (e.g., IL -1β, TNF a, IL -6) [35]. These results confirm that miR -146a-5p acts to attenuate the
microglial inflammatory state.
Figure 5. Network view for T-DEMs and gene targets. (A) miRNet 2.0 view for the 6 identified T -DEMs (blue
square) and their experimentally validated targets (pink marker, 244 genes). Genes connect ing several
miRNAs are labelled. The dominant connection of miR -155-5p is evident. (B) STRING view for a set of 21
protein coding targets (T -DEGs, Table 2 ). The protein -protein interaction (PPI) network is significant (PPI
enrichment p-value: 0.00986). Enrichment of gene ontology biological process (GO_BP) of Immune system
process (GO:0002376) and Regulation of cytokine production (GO:0001817) are colored r ed and blue,
respectively (p -value 3.4 e -06). (C) The functional enrichment of the listed genes (21 genes, Table 2) by
Reactome pathways. From left to right: The fraction of gene input (red); Significant pathways by Reactome
are sorted by p-values (blue); The overlapping genes for each of Reactome’s enriched pathways (orange).
.CC-BY-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 14, 2025. ; https://doi.org/10.1101/2025.04.11.648484doi: bioRxiv preprint
11
Nlrp3 is one of the genes most strongly expressed after microglial activation. The assembly of the NLRP3
inflammasome leads to the release of the pro -inflammatory cytokine, IL-1β. While no direct effect of miR -
7a-5p on Nlrp3 was shown in microglial cells. miR -7a-5p is highly expressed and known to play a role in
modulating neuroinflammation by directly target ing Nlrp3, resulting in reduced pro-inflammatory cytokine
production. Over half of all targeted genes to T -DEMs are annotated as ‘regulation of cytokine production’
(GO:0001817; enrichment p-value 3.4e-06). We conclude that miR-146a-5p acts to attenuate the microglial
inflammatory state. While Figure 5A presents overall interactions of miRNAs with validated target genes from
any tissue, Figure 5B shows protein-protein interaction (PPI) network of target T-DEGs, as identified by RNA-
seq from bzATP/LPS activated microglia [15]. Many of the listed genes belon g to cytokine release and
immune-related categories. We further tested the miRNA-target pairs (Table 2) by examining the pathways
represented in Reactome [36]. Figure 5C presented an enrichment analysis for the set of pathways that
dominate the input genes. We show that cytokine signaling, interleukins, and TCR pathways are very
significant. Other pathways indicate that a large fraction of the input gene list was implicated in the NLR3
inflammasome.
Ladostigil induced miRNAs that may serve as mediators in suppressing inflammation
Analysis of miRNA profiles in the activation protocol Indicated that the system is suitable for pharmacological
manipulation and analysis [37]. Accordingly, we examined the effect of ladostigil on miRNA profiles.
Ladostigil, an aminoindan derivative [38] has been shown to reduce the produ ction and secretion of pro -
inflammatory cytokines [17]. RNA-seq analysis revealed that Egr1, Egr2 (Early growth response protein 1 and
2) and several metalloproteinases (MMPs) were upregulated following microglia activat ion protocol while
incubation of ladostigil significantly reversed this trend [17, 37]. We wanted to determine whether miRNAs
could be the mediators controlling the overall reduction in the inflammatory state of microglia. miRNAs may
exert their function by several modes of action including cellular relocation [39], loading into AGO proteins
for stabilization, indirect competition with other RNAs [40]. In a a short time-window, the miRNA profile was
compared between to that in N.T. (with 2 h incubati on with ladostigil) and 3 h following full activation. We
found that none of the 372 identified miRNAs was significantly altered (Figure 6A). We concluded that miRNA
expression changes were not involved in the immediate response to ladostigil. However, at 8 h ladostigil,
significantly upregulated 4 miRNAs: miR-23b-5p (1.48-fold), miR-27a-5p, miR-27b-5p (1.27-1.28-fold; Figure
6B, Supplementary Table S7) and miR-365-2-5p (1.93-fold). While the role of miR-365-2-5p is not known, the
other miRNAs have previously been implicated in inflammation suppression (Table 3). Despite the relatively
moderate fold changes in miR -27a and miR -27b, they are highly abundant and thus may be involved is
suppression of multiple targets (average amounts in microglia i s 532.2 and 167.5 CPM, respectively).
Specifically, miR-27b counteracted the effects of TNF a and was linked to restoring mitochondrial function ,
reducing apoptosis , and the Akt/Foxo1 pathway [41]. Others have shown that changes in miR -23b are
associated with PD [42], and have been implicated in the oxidative stress response [43] and in suppressing
α-synuclein expression. In mice with induced sepsis, miR-23b-5p was reduced, coupled with the elevation in
ADAM10 and o ther MMPs. Expression of m etalloproteases increased in the activated microglia, was
suppressed by ladostigil, together with the decrease in the levels of inflammatory cytokine (TNF-α, IL-1β, IL-
6) [17].
.CC-BY-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 14, 2025. ; https://doi.org/10.1101/2025.04.11.648484doi: bioRxiv preprint
12
Figure 6. The effect of ladogtigil on miRNA expression . MA plots of the log2(FC) relative to the CPM (in log)
for the 372 identified miRNAs in a fully activated setting (bzATP/LPS). (A) 3 h post activation relative to N.T.
(B) 8 h post activation relative to N.T. The miRNAs that were upregulated by ladostigil are marked in red font.
Gray color are miRNAs that showed no significant expression change. The change in expression was
determined by a threshold of log2(FC) > |0.33| and an FDR q -value <0.05. The dashed lines mark stable
expression.
Table 3 summarizes the current knowledge on the link between the overexpression of miRNAs and their
potential targets that dr ive inflammation reduction. We conclude that ladostigil induces a restricted set of
miRNAs that enhance the ability of the cells to cope with oxidative stress and the induction of pro -
inflammatory signature of the treated cells. The central role of miRNAs in attenuating NF-kB signaling (Table
3) is in accord with the significance of this pathway in the modulation by ladostigil in other cellular systems
(e.g., [37]).
Table 3. Upregulation by ladostigil of miRNAs that act in reducing inflammation in multiple model systems
miRNA Activation /Condition Cellular and Modela Target gene/ pathwayb Refrerence
miR-23b-5p intracerebral hemorrhage (ICH) Rat brain IPMK
[44]
Sepsis-Induced Mouse MMP/ ADAM10 [45]
miR-27a-5p
LPS activated Human dental pulp cells (hDPCs) TAB1/NF-κB [46]
Clostridioides infection Mouse Intestine NF-κB signaling [47]
Salmonella infection EVs, RAW264.7 cells TLR7/ NF-κB [48]
miR-27b-5p
TNF alpha exposure Human aortic endothelial cells
(HAECs) Akt-FOXO1 [41]
Mycobacterium Infection RAW264.7 cells NF-κB signaling [49]
Hydrogen peroxide induced RAW264.7 cells NF-κB signaling [50]
IL-1β-induced Human osteoarthritis chondrocytes MMP-13/NF-kB/ p38 [51]
aEVs, exosomal vesicles; RAW264.7 are mouse derived cell line of peripheral macrophages. SW -1353 are
human chondrosarcoma cell line. bIPMK, Inositol polyphosphate multikinase; ADAM10, ADAM
metallopeptidase domain 10; TAB1, TGF-beta activated kinase 1/MAP3K7 binding protein 1; TLR7, Toll -like
receptor 7.
References
1. Thakur, S.; Dhapola, R.; Sarma, P.; Medhi, B.; Reddy, D. H., Neuroinflammation in Alzheimer’s disease:
current progress in molecular signaling and therapeutics. Inflammation 2023, 46, (1), 1-17.
2. Voet, S.; Srinivasan, S.; Lamkanfi, M.; van Loo, G., Infla mmasomes in neuroinflammatory and
neurodegenerative diseases. EMBO molecular medicine 2019, 11, (6), e10248.
3. Zhang, W.; Xiao, D.; Mao, Q.; Xia, H., Role of neuroinflammation in neurodegeneration development.
Signal transduction and targeted therapy 2023, 8, (1), 267.
4. Leng, F.; Edison, P., Neuroinflammation and microglial activation in Alzheimer disease: where do we
go from here? Nature Reviews Neurology 2021, 17, (3), 157-172.
5. Von Bernhardi, R.; Eugenín-von Bernhardi, L.; Eugenín, J., Microglial cell dysregulation in brain aging
and neurodegeneration. Frontiers in aging neuroscience 2015, 7, 124.
6. Raffaele, S.; Lombardi, M.; Verderio, C.; Fumagalli, M., TNF production and release from microglia via
extracellular vesicles: impact on brain functions. Cells 2020, 9, (10), 2145.
7. Rajendran, L.; Paolicelli, R. C., Microglia -mediated synapse loss in Alzheimer's disease. Journal of
Neuroscience 2018, 38, (12), 2911-2919.
8. Zhang, G.; Wang, Z.; Hu, H.; Zhao, M.; Sun, L., Microglia in Alzheimer’s dis ease: a target for
therapeutic intervention. Frontiers in Cellular Neuroscience 2021, 15, 749587.
9. Shoham, S.; Linial, M.; Weinstock, M., Age-induced spatial memory deficits in rats are correlated with
specific brain region alterations in microglial morp hology and gene expression. Journal of
Neuroimmune Pharmacology 2019, 14, 251-262.
10. Colonna, M.; Butovsky, O., Microglia Function in the Central Nervous System During Health and
Neurodegeneration. Annu Rev Immunol 2017, 35, 441-468.
11. Butovsky, O.; Jedrychowski, M. P.; Moore, C. S.; Cialic, R.; Lanser, A. J.; Gabriely, G.; Koeglsperger, T.;
Dake, B.; Wu, P. M.; Doykan, C. E.; Fanek, Z.; Liu, L.; Chen, Z.; Rothstein, J. D.; Ransohoff, R. M.; Gygi,
S. P.; Antel, J. P.; Weiner, H. L., Identification of a unique TGF -beta-dependent molecular and
functional signature in microglia. Nat Neurosci 2014, 17, (1), 131-43.
12. Hemonnot, A.-L.; Hua, J.; Ulmann, L.; Hirbec, H., Microglia in Alzheimer disease: well-known targets
and new opportunities. Frontiers in aging neuroscience 2019, 11, 233.
13. Al-Ghraiybah, N. F.; Wang, J.; Alkhalifa, A. E.; Roberts, A. B.; Raj, R.; Yang, E.; Kaddoumi, A., Glial Cell-
Mediated Neuroinflammation in Alzheimer's Disease. Int J Mol Sci 2022, 23, (18).
.CC-BY-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 14, 2025. ; https://doi.org/10.1101/2025.04.11.648484doi: bioRxiv preprint
15
14. Potru, P. S.; Vidovic, N.; W iemann, S.; Russ, T.; Trautmann, M.; Spittau, B., A Custom Panel for
Profiling Microglia Gene Expression. Cells 2024, 13, (7).
15. Zohar, K.; Lezmi, E.; Reichert, F.; Eliyahu, T.; Rotshenker, S.; Weinstock, M.; Linial, M., Coordinated
Transcriptional Waves Define the Inflammatory Response of Primary Microglial Culture. Int J Mol Sci
2023, 24, (13).
16. Linial, M.; Stern, A.; Weinstock, M., Effect of ladostigil treatment of aging rats on gene expression in
four brain areas associated with regulation of memory. Neuropharmacology 2020, 177, 108229.
17. Reichert, F.; Zohar, K.; Lezmi, E.; Eliyahu, T.; Rotshenker, S.; Linial, M.; Weinstock, M., Ladostigil
Reduces the Adenoside Triphosphate/Lipopolysaccharide -Induced Secretion of Pro -Inflammatory
Cytokines from Microglia and Modulate-Immune Regulators, TNFAIP3, and EGR1. Biomolecules 2024,
14, (1), 112.
18. He, Y.; Yao, X.; Taylor, N.; Bai, Y.; Lovenberg, T.; Bhattacharya, A., RNA sequencing analysis reveals
quiescent microglia isolation methods from postnatal mouse brains and limitations of BV2 cells. J
Neuroinflammation 2018, 15, (1), 153.
19. Thounaojam, M. C.; Kaushik, D. K.; Basu, A., MicroRNAs in the brain: it's regulatory role in
neuroinflammation. Mol Neurobiol 2013, 47, (3), 1034-44.
20. Hussein, M.; Magdy, R., MicroRNAs in central nervous system disorders: current advances in
pathogenesis and treatment. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery 2021,
57, (1), 36.
21. Guo, Y.; Hong, W.; Wang, X.; Zhang, P.; Korner, H.; Tu, J.; Wei, W., MicroRNAs in Microglia: How do
MicroRNAs Affect Activation, Inflammation, Polarizati on of Microglia and Mediate the Interaction
Between Microglia and Glioma? Front Mol Neurosci 2019, 12, 125.
22. Reichert, F.; Rotshenker, S., Complement-receptor-3 and scavenger-receptor-AI/II mediated myelin
phagocytosis in microglia and macrophages. Neurobiology of disease 2003, 12, (1), 65-72.
23. Gitik, M.; Liraz -Zaltsman, S.; Oldenborg, P. -A.; Reichert, F.; Rotshenker, S., Myelin down -regulates
myelin phagocytosis by microglia and macrophages through interactions between CD47 on myelin
and SIRPα (signal regulatory protein-α) on phagocytes. Journal of neuroinflammation 2011, 8, 1-11.
24. Dobin, A.; Davis, C. A.; Schlesinger, F.; Drenkow, J.; Zaleski, C.; Jha, S.; Batut, P.; Chaisson, M.;
Gingeras, T. R., STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013, 29, (1), 15-21.
25. Friedlander, M. R.; Mackowiak, S. D.; Li, N.; Chen, W.; Rajewsky, N., miRDeep2 accurately identifies
known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res 2012, 40,
(1), 37-52.
26. Robinson, M. D.; McCarthy, D. J.; Smyth, G. K., edgeR: a Bioconductor package for differential
expression analysis of digital gene expression data. Bioinformatics 2010, 26, (1), 139-40.
27. Szklarczyk, D.; Gable, A. L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva,
N. T.; Morris, J. H.; Bork, P., STRING v11: protein –protein association networks with increased
coverage, supporting functional discovery in genome -wide experimental datasets. Nucleic acids
research 2019, 47, (D1), D607-D613.
28. Chang, L.; Zhou, G.; Soufan, O.; Xia, J., miRNet 2.0: network -based visual analytics for miRNA
functional analysis and systems biology. Nucleic acids research 2020, 48, (W1), W244-W251.
29. Sayed, M.; Park, J. W., miRinGO: Prediction of biological proce sses indirectly targeted by human
microRNAs. Non-coding RNA 2023, 9, (1), 11.
30. Xu, F.; Wang, Y.; Ling, Y.; Zhou, C.; Wang, H.; Teschendorff, A. E.; Zhao, Y.; Zhao, H.; He, Y.; Zhang, G.,
dbDEMC 3.0: functional exploration of differentially expressed miR NAs in cancers of human and
model organisms. Genomics, Proteomics and Bioinformatics 2022, 20, (3), 446-454.
31. Mahlab-Aviv, S.; Linial, N.; Linial, M., miRNA Combinatorics and its Role in Cell State Control —A
Probabilistic Approach. Frontiers in Molecular Biosciences 2021, 8, 772852.
32. Iwakawa, H. O.; Tomari, Y., The Functions of MicroRNAs: mRNA Decay and Translational Repression.
Trends Cell Biol 2015, 25, (11), 651-665.
33. Remenyi, J.; van den Bosch, M. W.; Palygin, O.; Mistry, R. B.; McKenzie, C.; Macdonald, A.; Hutvagner,
G.; Arthur, J. S.; Frenguelli, B. G.; Pankratov, Y., miR -132/212 knockout mice reveal ro les for these
miRNAs in regulating cortical synaptic transmission and plasticity. PLoS One 2013, 8, (4), e62509.
34. Huang, Y.; Lin, X.; Lin, X., MiR -146a-5p Contributes to Microglial Polarization Transitions Associated
With AGEs. Mol Neurobiol 2023, 60, (6), 3020-3033.
.CC-BY-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 14, 2025. ; https://doi.org/10.1101/2025.04.11.648484doi: bioRxiv preprint
16
35. Martin, N. A.; Hyrlov, K. H.; Elkjaer, M. L.; Thygesen, E. K.; Wlodarczyk, A.; Elbaek, K. J.; Aboo, C.;
Okarmus, J.; Benedikz, E.; Reynolds, R.; Hegedus, Z.; Stensballe, A.; Svenningsen, A. F.; Owens, T.;
Illes, Z., Absence of miRNA -146a Differentially Alters Microglia Function and Proteome. Front
Immunol 2020, 11, 1110.
36. Gillespie, M.; Jassal, B.; Stephan, R.; Milacic, M.; Rothfels, K.; Senff -Ribeiro, A.; Griss, J.; Sevilla, C.;
Matthews, L.; Gong, C., The reactome pathway knowledgeba se 2022. Nucleic acids research 2022,
50, (D1), D687-D692.
37. Zohar, K.; Lezmi, E.; Eliyahu, T.; Linial, M., Ladostigil attenuates induced oxidative stress in human
neuroblast-like SH-SY5Y cells. Biomedicines 2021, 9, (9), 1251.
38. Schneider, L. S.; Geff en, Y.; Rabinowitz, J.; Thomas, R. G.; Schmidt, R.; Ropele, S.; Weinstock, M.;
Group, L. S., Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical
trial. Neurology 2019, 93, (15), e1474-e1484.
39. van Wijk, N.; Zohar, K.; Linial, M., Challenging cellular homeostasis: Spatial and temporal regulation
of miRNAs. International journal of molecular sciences 2022, 23, (24), 16152.
40. Reichholf, B.; Herzog, V. A.; Fasching, N.; Manzenreither, R. A.; Sowemimo, I.; Ameres, S. L., Time-
Resolved Small RNA Sequencing Unravels the Molecular Principles of MicroRNA Homeostasis. Mol
Cell 2019, 75, (4), 756-768 e7.
41. D'Onofrio, N.; Prattichizzo, F.; Martino, E.; Anastasio, C.; Mele, L.; La Grotta, R.; Sardu, C.; Ceriello,
A.; Marfella, R.; Paolisso, G.; Balestrieri, M. L., MiR-27b attenuates mitochondrial oxidative stress and
inflammation in endothelial cells. Redox Biol 2023, 62, 102681.
42. Xu, K.; Li, Y.; Zhou, Y.; Zhang, Y.; Shi, Y.; Zhang, C.; Bai, Y.; Wang, S., Neuroinflammation in Parkinson's
disease: focus on the relationship between miRNAs and microglia. Front Cell Neurosci 2024, 18,
1429977.
43. Geng, X.; Zou, Y.; Li, S.; Qi, R.; Yu, H.; Li, J., MALAT1 Mediates alpha -Synuclein Expression through
miR-23b-3p to Induce Autophagic Im pairment and the Inflammatory Response in Microglia to
Promote Apoptosis in Dopaminergic Neuronal Cells. Mediators Inflamm 2023, 2023, 4477492.
44. Hu, L.; Zhang, H.; Wang, B.; Ao, Q.; Shi, J.; He, Z., MicroRNA -23b alleviates neuroinflammation and
brain in jury in intracerebral hemorrhage by targeting inositol polyphosphate multikinase. Int
Immunopharmacol 2019, 76, 105887.
45. Zhang, W.; Lu, F.; Xie, Y.; Lin, Y.; Zhao, T.; Tao, S.; Lai, Z.; Wei, N.; Yang, R.; Shao, Y.; He, J., miR -23b
Negatively Regulates Sepsis-Induced Inflammatory Responses by Targeting ADAM10 in Human THP-
1 Monocytes. Mediators Inflamm 2019, 2019, 5306541.
46. Wang, S.; Kawashima, N.; Han, P.; Sunada-Nara, K.; Yu, Z.; Tazawa, K.; Fujii, M.; Kieu, T. Q.; Okiji, T.,
MicroRNA-27a-5p Downregulates Expression of Proinflammatory Cytokines in Lipopolysaccharide -
Stimulated Human Dental Pulp Cells via the NF-kappaB Signaling Pathway. Int J Mol Sci 2024, 25, (17).
47. Kobeissy, P. H.; Deneve -Larrazet, C.; Marvaud, J. C.; Kansau, I., MicroRNA miR -27a-5p Reduces
Intestinal Inflammation Induced by Clostridioides difficile Flagella by Regulating the Nuclear Factor -
kappaB Signaling Pathway. J Infect Dis 2025, 231, (1), e38-e46.
48. Qu, M.; Su, S.; Jiang, L.; Yu, X.; Zhang, J.; Zhu, H.; Han, K.; Zhang, X., Exosomal miR-27a-5p attenuates
inflammation through Toll -like receptor 7 in foodborne Salmonella infections. Vet Microbiol 2025,
302, 110394.
49. Liang, S.; Song, Z.; Wu, Y. ; Gao, Y.; Gao, M.; Liu, F.; Wang, F.; Zhang, Y., MicroRNA -27b Modulates
Inflammatory Response and Apoptosis during Mycobacterium tuberculosis Infection. J Immunol
2018, 200, (10), 3506-3518.
50. Thulasingam, S.; Massilamany, C.; Gangaplara, A.; Dai, H.; Yarbaeva, S.; Subramaniam, S.; Riethoven,
J. J.; Eudy, J.; Lou, M.; Reddy, J., miR -27b*, an oxidative stress -responsive microRNA modulates
nuclear factor-kB pathway in RAW 264.7 cells. Mol Cell Biochem 2011, 352, (1-2), 181-8.
51. Akhtar, N.; Rasheed, Z.; Ramamurthy, S.; Anbazhagan, A. N.; Voss, F. R.; Haqqi, T. M., MicroRNA-27b
regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes.
Arthritis Rheum 2010, 62, (5), 1361-71.
52. Deora, V.; Lee, J. D.; Albornoz, E. A.; McAlary, L.; Jagaraj, C. J.; Robertson, A. A. B.; Atkin, J. D.; Cooper,
M. A.; Schroder, K.; Yerbury, J. J.; Gordon, R.; Woodruff, T. M., The microglial NLRP3 inflammasome
is activated by amyotrophic lateral sclerosis proteins. Glia 2020, 68, (2), 407-421.
.CC-BY-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 14, 2025. ; https://doi.org/10.1101/2025.04.11.648484doi: bioRxiv preprint
17
53. Parisi, C.; Arisi, I.; D'Ambrosi, N.; Storti, A. E.; Brandi, R.; D'Onofrio, M.; Volonte, C., Dysregulated
microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation.
Cell Death Dis 2013, 4, (12), e959.
54. Jablonski, K. A.; Gaudet, A. D.; Amici, S. A.; Popovich, P. G.; Guerau -de-Arellano, M., Control of the
Inflammatory Macrophage Transcriptional Signature by miR-155. PLoS One 2016, 11, (7), e0159724.
55. Zingale, V. D.; Gugliandolo, A.; Mazzon, E., MiR-155: An Important Regulator of Neuroinflammation.
Int J Mol Sci 2021, 23, (1).
56. Meldolesi, J., Exosomes and ectosomes in intercellular communication. Current Biology 2018, 28, (8),
R435-R444.
57. Jin, X. F.; Wu, N.; Wang, L.; Li, J., Circulating microRNAs: a novel clas s of potential biomarkers for
diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol 2013, 33, (5), 601-
13.
58. Long, X.; Yao, X.; Jiang, Q.; Yang, Y.; He, X.; Tian, W.; Zhao, K.; Zhang, H., Astrocyte-derived exosomes
enriched with m iR-873a-5p inhibit neuroinflammation via microglia phenotype modulation after
traumatic brain injury. J Neuroinflammation 2020, 17, (1), 89.
59. Harrison, E. B.; Hochfelder, C. G.; Lamberty, B. G.; Meays, B. M.; Morsey, B. M.; Kelso, M. L.; Fox, H.
S.; Yelamanchili, S. V., Traumatic brain injury increases levels of miR -21 in extracellular vesicles:
implications for neuroinflammation. FEBS Open Bio 2016, 6, (8), 835-46.
60. Chen, Y. F.; Luh, F.; Ho, Y. S.; Yen, Y., Exosomes: a review of biologic function, diagnostic and targeted
therapy applications, and clinical trials. J Biomed Sci 2024, 31, (1), 67.
61. Chevillet, J. R.; Kang, Q.; Ruf, I. K.; Briggs, H. A.; Vojtech, L. N.; Hughes, S. M.; Cheng, H. H.; Arroyo, J.
D.; Meredith, E. K.; Gallichotte, E. N.; Pogosova -Agadjanyan, E. L.; Morrissey, C.; Stirewalt, D. L.;
Hladik, F.; Yu, E. Y.; Higano, C. S.; Tewari, M., Quantitative and stoichiometric analy sis of the
microRNA content of exosomes. Proc Natl Acad Sci U S A 2014, 111, (41), 14888-93.
.CC-BY-ND 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
The copyright holder for this preprintthis version posted April 14, 2025. ; https://doi.org/10.1101/2025.04.11.648484doi: bioRxiv preprint